Clinical trials: Seizures Disorders
Partial Seizure
An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.
An open label, balanced, randomized, 3×3 latin square design comparing of Brivaracetam sustained-release tablets and Brivaracetam tablets in the oral comparative pharmacokinetic(PK) study in Chinese healthy adult subjects under…
- Trial name
- NCT05622370
- Testing
- Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB), Brivaracetam sustained-release tablets 100mg, Brivaracetam sustained-release tablets 50mg
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Overseas Pharmaceuticals, Ltd.
Epilepsy, Generalized Tonic-clonic Seizures
A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures
To evaluate the efficacy and safety of Levetiracetam dry syrup at doses up to 60 mg/kg/day or 3000 mg/day used as adjunctive therapy in Japanese pediatric patients aged ≥4 to <16 years with uncontrolled Generalized Tonic-Clonic…
- Trial name
- NCT01292837
- Testing
- Levetiracetam
- Where
- 26 sites in Japan
- Volunteers
- 13 people
- Sponsor
- UCB Japan Co. Ltd.
Hearing Loss
Assessment of Novel Measurement and Fitting Methods to Determine Their Reliability, Validity and Application - Sonova2018_34
A methodical evaluation of novel measurement and fitting methods for individualizing CE-labelled Sonova brand hearing instruments (e.g. Phonak hearing instruments) is intended to be conducted on hearing impaired participants.
- Trial name
- NCT03755453
- Testing
- Hearing aid: Phonak Audéo B90-Direct
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Sonova AG
Epilepsy, Tonic-Clonic
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures.
- Trial name
- NCT00104416
- Testing
- lamotrigine (LAMICTAL) extended-release
- Where
- 146 sites in United States, Argentina and 9 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Epilepsy
GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures
Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin
- Trial name
- NCT00567424
- Testing
- GW273225
- Where
- 30 sites in United States
- Sponsor
- GlaxoSmithKline
Epilepsy; Seizure, Focal Epilepsy
Seizures Detection in Real Life Setting
Epilepsy is a disabling neurological disease that affects tens of millions of people worldwide. Despite therapeutic advances, about a third of these patients suffer from treatment-resistant forms of epilepsy and still experience…
- Trial name
- ECEME (NCT05635396)
- Testing
- Wearable, non invasive sensor for seizure detection
- Volunteers
- 12 people
- Sponsor
- Reliev Technologies
Partial Onset Seizures
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to <4 years of age with refractory partial onset seizures.
- Trial name
- NCT02072824
- Testing
- Pregabalin Dose Level 1, Pregabalin Dose Level 2
- Where
- 72 sites in United States, Belarus and 21 more
- Volunteers
- 175 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Partial Onset Seizures
Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures
This study is designed to provide short term efficacy and safety data of TRI476 in children with inadequately-controlled partial seizures.
- Trial name
- NCT00975715
- Testing
- TRI476, Benzodiazepines
- Where
- 25 sites in Japan
- Volunteers
- 99 people
- Sponsor
- Novartis Pharmaceuticals
Unilateral Deafness
Evaluation of BiCROS Fitting Benefits
22 candidates for BiCROS hearing aids will be recruited and fitted with a hearing aid and a CROS device. Following a real-world trial, each participant will be tested on a range of outcome measures including speech recognition in…
- Trial name
- NCT05379231
- Testing
- Hearing aid fitting
- Where
- 2 sites in Canada
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Sonova AG
Focal Onset Seizures
A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy
The purpose of this study is to evaluate the efficacy of up to 3 dose levels of adjunctive JNJ-40411813 compared to placebo based on the time to baseline monthly seizure count in participants with focal onset seizures who are…
- Trial name
- NCT04836559
- Testing
- JNJ-40411813
- Where
- 69 sites in United States, Belgium and 6 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Epilepsy
PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1
This is a post-market, open observational long-term effectiveness follow-up study of participants with drug-resistant epilepsy with partial-onset seizures previously enrolled in a randomized controlled trial (PuLsE) comparing…
- Trial name
- PuLsE 2 (NCT01281280)
- Where
- 18 sites in Belgium, Canada and 5 more
- Volunteers
- 81 people
- Sponsor
- Cyberonics, Inc.
Partial Epilepsies
To Determine Tolerability and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
The purpose of this trial is to determine whether lacosamide is safe and effective for long-term use in patients with partial-seizures from epilepsy.
- Trial name
- NCT00552305
- Testing
- lacosamide
- Where
- 59 sites in United States, Germany and 6 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma
Hearing Loss
Tuned App Self-Fitting vs. Professional Fitting
The aim of the study is to compare the perceived outcome of the self-fitting performed by the participants using the Tuned mobile application with the traditional professional fitting as performed by a licensed professional…
- Trial name
- NCT05869266
- Testing
- professional fitting vs. self fitting
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Tuned Ltd.
Epilepsy, Partial-Onset Seizures
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.
- Conditions
- Epilepsy, Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT02736162
- Testing
- No treatment (intervention) was administered
- Volunteers
- 61 people
- Sponsor
- Eisai Inc.
Lennox Gastaut Syndrome, Dravet Syndrome
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- EpiTALY (NCT05485831)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- 18 sites in Italy
- Volunteers
- 111 people
- Sponsor
- Jazz Pharmaceuticals
Seizures, Seizures, Focal
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures.
- Conditions
- Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial
- Trial name
- NCT06534502
- Testing
- Zonisamide Oral Product
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Azurity Pharmaceuticals
Lennox-Gastaut Syndrome
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
This Phase 3 trial will enroll participants diagnosed with Lennox-Gastaut Syndrome (LGS) who are still experiencing at least 4 motor seizures involving the trunk or extremities per week, despite ongoing treatment with up to 3…
- Trial name
- NCT02318537
- Testing
- Cannabidiol Oral Solution
- Sponsor
- INSYS Therapeutics Inc
Partial Epilepsy
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance…
- Trial name
- NCT01866111
- Testing
- YKP3089
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 437 people
- Sponsor
- SK Life Science, Inc.
Epilepsy
Pediatric Epilepsy Study
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as monotherapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
- Trial name
- NCT00050947
- Testing
- oxcarbazepine
- Where
- 30 sites in United States, Brazil and 2 more
- Volunteers
- 94 people
- Sponsor
- Novartis Pharmaceuticals
Partial Seizures
A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
The primary objective of the present study will be to assess the effectiveness of add-on perampanel in participants with focal seizures in a real-life clinical setting.
- Trial name
- NCT04257604
- Testing
- Perampanel
- Volunteers
- 243 people
- Sponsor
- Eisai Limited